SCHEMBL8213600

SCHEMBL8213600

C[C@@H](CO)[C@H]1CC[C@H]2[C@@H](O[Si](C)(C)C(C)(C)C)CCC[C@]12C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 4/20 0.47
CDC25B P30305 2/20 0.47
DHCR24 Q15392 1/20 0.36
PPM1D O15297 2/20 0.36
SRD5A2 P31213 1/20 0.36
GPBAR1 Q8TDU6 2/20 0.33
AKR1B10 O60218 1/20 0.33
AKR1B1 P15121 1/20 0.33
EFNA1 P20827 1/20 0.33
EPHA2 P29317 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13343106 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL13343110 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL3182269 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL3182273 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL14107824 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL14005368 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL13343108 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL14107823 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL3182280 1.00 CDC25A (0.47) CDC25ACDC25BDHCR24PPM1DSRD5A2
SCHEMBL8201371 0.94 CDC25A (0.42) CDC25ACDC25BDHCR24PPM1DSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440647-B2 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-05-14 US disclosed
US-8188064-B2 Reducing cell differentiation of adipocyte; reducing body fat WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-05-29 US disclosed
US-8188064-B2 Reducing cell differentiation of adipocyte; reducing body fat WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-05-29 US disclosed
US-7915242-B2 eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-03-29 US disclosed
US-7713952-B2 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-05-11 US disclosed
US-20070270391-A1 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses WISCONSIN ALUMNI RESEARCH FOUNDATION, A NON-STOCK, NON-PROFIT WISCONSIN CORPORATION (US) 2007-11-22 US disclosed
US-20070249567-A1 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-10-25 US disclosed
US-20070219168-A1 19,26,27-TRINOR-1alpha,25-DIHYDROXYVITAMIN D3 COMPOUNDS WISCONSIN ALUMNI RESEARCH FOUNDATION 2007-09-20 US disclosed
US-7244719-B2 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-07-17 US disclosed
US-7241909-B2 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-07-10 US disclosed
US-6153605-A Arylsecocholadiene derivatives HOFFMAN-LA ROCHE INC. (US) 2000-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270391-A1 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses CYP24A1, CYP27B1, CD14 CDC25A 399/4885CDC25B 520/4885DHCR24 212/4885
US-20070219168-A1 19,26,27-TRINOR-1alpha,25-DIHYDROXYVITAMIN D3 COMPOUNDS CYP24A1, CYP2R1, CYP27B1 CDC25A 866/4885CDC25B 1674/4885DHCR24 50/4885
US-20070249567-A1 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses CYP27B1, CYP24A1, VDR CDC25A 980/4885CDC25B 1218/4885DHCR24 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.